Novel insights in folate receptors and transporters: Implications for disease and treatment of immune diseases and cancer

Pteridines

Volumn 26, Issue 2, 2015, Pages 41-53

  Jansen, Gerrit ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

folate deficiency; folate imaging; folate receptor; proton coupled folate transporter; reduced folate transporter

Indexed keywords

FOLATE RECEPTOR; FOLATE TRANSPORTER; FOLIC ACID;

AUTOIMMUNE DISEASE; CANCER THERAPY; ENZYME REGULATION; FOLIC ACID DEFICIENCY; HUMAN; NEPHROLOGIST; ONCOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 84930439141     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pterid-2015-0005     Document Type: Review

References (108)

1. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-84.
2. Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci 2006;11:506-19.
3. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999;23:228-32.
4. Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999;85:348-57.
5. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009;113:438-46.
6. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007;27:145-59.
7. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci 2000;113 Pt 2:349-57.
8. Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013;500:486-9.
9. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci USA 2013;110: 15180-8.
10. Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 2014;17:89-95.
11. Muller C, Schibli R. Prospects in folate receptor-targeted radionuclide therapy. Front Oncol 2013;3:249.
12. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005;65:11721-8.
13. Van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60:12-21.
14. Jansen G, Van der Heijden JW, Dijkmans BA. Folate receptor-beta: a novel target for therapeutic intervention inrheumatoid arthritis? Int J Clin Rheumatol 2009;4:109-13.
15. Leamon CP, Jackman AL. Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm 2008;79:203-33.
16. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28.
17. Zhao R, Goldman ID. The proton-coupled folate transporter: physiological and pharmacological roles. Curr Opin Pharmacol 2013;13:875-80.
18. Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, et al. Structure-activity profiles of novel 6-substituted pyrrolo[2, 3-d] pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors alpha and beta and the proton-coupled folate transporter. J Med Chem 2014;57:8152-66.
19. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, et al. Carrier-and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol Pharmacol 1995;48:459-71.
20. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15:183-210.
21. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of anti-folates. Invest New Drugs 2006;24:37-77.
22. Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther 2012;13:1355-73.
23. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
24. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006;9:227-46.
25. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16:5288-95.
26. Marchetti C, Palaia I, Giorgini M, De MC, Iadarola R, Vertechy L, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther 2014;7:1223-36.
27. Zacchetti A, Coliva A, Luison E, Seregni E, Bombardieri E, Gius-sani A, et al. (177)Lu-labeled MOv18 as compared to (131)I-or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 2009;36:759-70.
28. Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother 2009;58:531-46.
29. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011;71:4617-27.
30. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315-9.
31. Sun JY, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, et al. In vivo optical imaging of folate receptor-beta in head and neck squamous cell carcinoma. Laryngoscope 2014;124:E312-9.
32. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41:120-9.
33. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007;12:808-15.
34. Kamen BA, Caston JD. Direct radiochemical assay for serum folate: competition between 3H-folic acid and 5-methyltetrahy-drofolic acid for a folate binder. J Lab Clin Med 1974;83:164-74.
35. Lacey SW, Sanders JM, Rothberg KG, Anderson RG, Kamen BA. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphati-dylinositol. J Clin Invest 1989;84:715-20.
36. Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 1986;83:5983-7.
37. Anderson RG, Kamen BA, Rothberg KG, Lacey SW. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992;255:410-1.
38. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RG. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988;263:13602-9.
39. Kamen BA, Smith AK, Anderson RG. The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest 1991;87:1442-9.
40. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Jr., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
41. Weitman SD, Frazier KM, Kamen BA. The folate receptor in central nervous system malignancies of childhood. J Neurooncol 1994;21:107-12.
42. Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, et al. Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. J Thorac Oncol 2014;9:519-26.
43. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4.
44. Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol 2014;76:251-74.
45. Blom HJ, Shaw GM, den HM, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 2006;7:724-31.
46. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis 2011;34:75-81.
47. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009;32:333-42.
48. Watkins D, Rosenblatt DS. Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity. Am J Med Genet 1989;34:427-34.
49. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab 2002;3:159-73.
50. Zhao R, Min SH, Qiu A, Sakaris A, Goldberg GL, Sandoval C, et al. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 2007;110:1147-52.
51. Lasry I, Berman B, Glaser F, Jansen G, Assaraf YG. Hereditary folate malabsorption: a positively charged amino acid at position 113 of the proton-coupled folate transporter (PCFT/SLC46A1) is required for folic acid binding. Biochem Biophys Res Commun 2009;386:426-31.
52. Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet 2009;85:354-63.
53. Grapp M, Wrede A, Schweizer M, Huwel S, Galla HJ, Snaidero N, et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun 2013;4:2123.
54. Della-Longa S, Arcovito A. Structural and functional insights on folate receptor alpha (FRalpha) by homology modeling, ligand docking and molecular dynamics. J Mol Graph Model 2013;44:197-207.
55. Tang YS, Khan RA, Zhang Y, Xiao S, Wang M, Hansen DK, et al. Incrimination of heterogeneous nuclear ribonucleoprotein E1 (hnRNP-E1) as a candidate sensor of physiological folate deficiency. J Biol Chem 2011;286:39100-15.
56. Salojin KV, Cabrera RM, Sun W, Chang WC, Lin C, Duncan L, et al. A mouse model of hereditary folate malabsorption: deletion of the PCFT gene leads to systemic folate deficiency. Blood 2011;117:4895-904.
57. Cario H, Smith DE, Blom H, Blau N, Bode H, Holzmann K, et al. Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease. Am J Hum Genet 2011;88:226-31.
58. Banka S, Blom HJ, Walter J, Aziz M, Urquhart J, Clouthier CM, et al. Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Hum Genet 2011;88:216-25.
59. Peters GJ, Kathmann I, Hooijberg JH, Losekoot N, Jansen G. Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression. Pteridines 2013;24:81-6.
60. Kugel DS, Wang L, Hales E, Polin L, White K, Kushner J, et al. Therapeutic targeting of a novel 6-substituted pyrrolo [2, 3-d] pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 2011;80:1096-107.
61. Wang L, Cherian C, Kugel DS, Mitchell-Ryan S, Hou Z, Matherly LH, et al. Synthesis and biological activity of 6-substituted pyrrolo[2, 3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem 2012;55:1758-70.
62. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
63. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thy-midylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
64. Gonen N, Bram EE, Assaraf YG. PCFT/SLC46A1 promoter meth-ylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun 2008;376:787-92.
65. Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, et al. Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed. Proc Amer Assoc Cancer Res 2015;56 (abstract 4335).
66. Yang C, Xie LY, Windle JJ, Taylor SM, Moran RG. Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human singlepromoter structure. FASEB J 2014;28:1998-2008.
67. Freemantle SJ, Moran RG. Transcription of the human folylpoly-gamma-glutamate synthetase gene. J Biol Chem 1997;272:25373-9.
68. Turner FB, Taylor SM, Moran RG. Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 2000;275:35960-8.
69. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Kaspers GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 1999;93: 1677-83.
70. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Henze G, et al. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2000;109:629-34.
71. Fotoohi K, Jansen G, Assaraf YG, Rothem L, Stark M, Kathmann I, et al. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 2004;104:4194-201.
72. Fotoohi AK, Assaraf YG, Moshfegh A, Hashemi J, Jansen G, Peters GJ, et al. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol 2009;77:1410-7.
73. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of anti-folate resistance in leukemia. Blood 2009;113:4362-9.
74. Wojtuszkiewicz A, Assaraf YG, Maas MJ, Kaspers GJ, Jansen G, Cloos J. Pre-mRNA splicing in cancer: the relevance in oncogen-esis, treatment and drug resistance. Expert Opin Drug Metab Toxicol 2015; in press.
75. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
76. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002;100:594-602.
77. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013;1:43-53.
78. Feng Y, Shen J, Streaker ED, Lockwood M, Zhu Z, Low PS, et al. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther 2011;13:R59.
79. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24:4254-61.
80. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42.
81. Leamon CP, Vlahov IR, Reddy JA, Vetzel M, Santhapuram HK, You F, et al. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship. Bioconjug Chem 2014;25:560-8.
82. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxo-rubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400-6.
83. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, et al. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res 2008;68:9839-44.
84. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011;89:557-63.
85. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
86. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
87. Jansen G, Weijers K, Blits M, Van der Heijden JW, Gent Y, Al M, et al. Folates and antifolates in rheumatoid arthritis. Pteridines 2013;24:21-6.
88. Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, et al. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum 2013;65:2791-802.
89. Van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, et al. Methotrexate analogues display enhanced inhibition of TNF-alpha production in whole blood from RA patients. Scand J Rheumatol 2014;43:9-16.
90. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012;39:2032-40.
91. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012;71:1484-9.
92. de Rotte MC, de Jong PH, Pluijm SM, Calasan MB, Barendregt PJ, van ZD, et al. Association of low baseline levels of eryth-rocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum 2013;65:2803-13.
93. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009;69:9395-403.
94. Samaniego R, Palacios BS, Domiguez-Soto A, Vidal C, Salas A, Matsuyama T, et al. Macrophage uptake and accumulation of folates are polarization-dependent in vitro and in vivo and are regulated by activin A. J Leukoc Biol 2014;95:797-808.
95. Tsuneyoshi Y, Tanaka M, Nagai T, Sunahara N, Matsuda T, Sonoda T, et al. Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand J Rheumatol 2012;41:132-40.
96. Nagai T, Kyo A, Hasui K, Takao S, Matsuyama T. Efficacy of an immunotoxin to folate receptor beta in the intra-articular treatment of antigen-induced arthritis. Arthritis Res Ther 2012;14:R106.
97. Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, et al. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 2009;58:1577-86.
98. Masteller EL, Wong BR. Targeting IL-34 in chronic inflammation. Drug Discov Today 2014;19:1212-6.
99. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 2011;41:749-59.
100. Shen J, Hilgenbrink AR, Xia W, Feng Y, Dimitrov DS, Lockwood MB, et al. Folate receptor-beta constitutes a marker for human proinflammatory monocytes. J Leukoc Biol 2014;96:563-70.
101. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013;10:507-18.
102. Snoeks TJ, van Driel PB, Keereweer S, Aime S, Brindle KM, van Dam GM, et al. Towards a successful clinical implementation of fluorescence-guided surgery. Mol Imaging Biol 2014;16:147-51.
103. Bruijnen ST, Gent Y Y, Voskuyl AE, Hoekstra OS, van der Laken CJ. Present role of positron emission tomography in the diagnosis and monitoring of peripheral inflammatory arthritis: a systematic review. Arthritis Care Res (Hoboken) 2014;66:120-30.
104. 18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther 2013;15:R37.
105. Chandrupatla DMSH, Weijers K, Gent YYJ, De Greeuw I, Lammertsma AA, Jansen G, et al. Sustained Macrophage infltration upon multi intra/articular injections, an improved rat model of rheumatoid arthritis for PET guided therapy evaluation. BioMed Research International 2015;2015:ID509295.
106. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy. Mol Cancer Ther 2013;12:2436-45.
107. 177Lu-radionuclide tumor therapy in mice. J Nucl Med 2013;54:124-31.
108. 47Sc for radionuclide tumor therapy in mice. J Nucl Med 2014;55:1658-64.